Clinical significance of drug resistance in HIV-1 infection

AIDS, Supplement

Volumn 10, Issue 5, 1996, Pages

  Kuritzkes, Daniel R ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Drug resistance; Lamivudine; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DISEASE COURSE; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SYNCYTIUM; TREATMENT FAILURE; VIRUS MUTATION;

EID: 0030499824     PISSN: 13502840     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199612005-00005     Document Type: Conference Paper

References (52)

1. Concorde Coordinating Committee: Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343:871-881.
2. Volberding PA, Lagakos SW, Grimes JM, et al.: The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994, 272:437-442.
3. Volberding P, Lagakos SW, Grimes JM, et al.: A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995, 333:401-407.
4. Ho, Neumann AU, Perelson AS: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
5. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type-1 infection. Nature 1995, 373:117-122.
6. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell lifetime, and viral generation time. Science 1995, 272:1582-1586.
7. Larder BA, Darby G, Richman DD: HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science 1989, 243:1731-1734.
8. Larder BA, Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246:1155-1158.
9. Boucher CAB, O'Sullivan E, Mulder JW, et al.: Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992, 165:105-110.
10. Larder BA, Kellam P, Kemp SD: Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991, 5:137-144.
11. De Jong MD, Veenstra J, Stilianakis N, et al.: Return to baseline values of HIV-1 RNA load during zidovudine treatment is associated with the emergence of K70R mutant virus. 4th International Workshop on HIV Drug Resistance. Sardinia, July 1995 [abstract 20].
12. Tudor-Williams G, St Clair MH, Mckinney RE, et al.: HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 1992, 339:15-19.
13. St Clair M, Hartigan PM, Andrews JC, et al.: Zidovudine resistance, syncytium-inducing phenotype and HIV disease progression in a case-control study: the VA Cooperative Study Group. J Acquir Immune Defic Syndr 1992 6:891-897.
14. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC: A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993, 167:526-532.
15. Husson RN, Shirasaka T, Bulter KM, Pizzo KM, Mitsuya H: High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy. J Pediatr 1993, 123:9-16.
16. Luque F, Caruz A, Pineda JA, Torres Y, Larder B, Leal M: Provirus load changes in untreated and zidovudine-treated human immunodeficiency virus type 1-infected patients. J Infect Dis 1994, 169:267-273.
17. Kozal MJ, Shafer RW, Winters MS, et al.: HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. J Acquir Immune Defic Syndr 1994, 7:832-838.
18. St Clair MH, Martin JL, Tudor-Williams G, et al.: Resistance to didanosine and sensitivity to zidovudine induced by a mutation in HIV-1 reverse transcriptase. Science 1991, 253:1557-1559.
19. Shafer RW, Kozal MJ, Winters MA, et al.: Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994, 169:722-729.
20. Schooley RT, Ramirez-Ronda C, Lange JMA, et al.: Virologic and immunologic benefits of initial therapy wirh zidovudine and zalcitabine or didanosine compared to zalcitabine monotherapy. J Infect Dis 1996, 173:1354-1356.
21. Zhang D, Caliendo AM, Eron JJ, et al.: Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1994, 38:282-287.
22. Gu Z, Gao Q, Fang J, et al.: Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994, 38:275-281.
23. Lacey SF, Larder BA: Novel nutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother 1994, 38:1428-1432.
24. Lin PF, Samanta H, Rose RE, et al.: Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994, 170:1157-1164.
25. Boucher CAB, Cammack N, Schipper P, et al.: High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993, 37:2231-2234.
26. Tisdale M, Kemp SD, Parry NR, Larder BA: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
27. Schinazi RF, Lloyd RM, Nguyen MH, et al.: Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993, 37:875-881.
28. Nijhuis M, de Jong D, van Leeuwen R, et al.: The rise in HIV-1 RNA load during 3TC/zidovudine combination therapy is associated with the selection of viruses resistant to both 3TC and zidovudine. 4th International Workshop on HIV Drug Resistance. Sardinia, July 1995 [abstract 52].
29. Kemp SD, Kohli A, Larder BA: Genotypic characterisation of an HIV-1 mutant co-resistant to zidovudine and 3TC. 4th International Workshop on HIV Drug Resistance. Sardinia, July 1995 [abstract 51].
30. 3). 4th International Workshop on HIV Drug Resistance. Sardinia, July 1995 [abstract 55].
31. Kuritzkes DR, Bakhtiari M, Shugarts D, et al.: Resistance to lamuivudine (3TC) and zidovudine (ZDV) after prolonged treatment with 3TC/ZDV. 5th International Workshop on HIV Drug Resistance. Whistler, July 1996 [abstract 57].
32. Nunberg JH, Schleif WA, Boots EJ, et al.: Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 1991, 65:4887-4892.
33. Richman D, Shin CK, Louy I, et al.: Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991, 88:11241-11245.
34. Dueweke TJ, Pushkarskaya T, Poppe SM, et al.: A novel mutation in bisheteroarylpiperazine-resistant HIV-1 reverse transcriptase confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 1993, 90:4713-4717.
35. Richman DD, Havlir D, Corbeil J, et al.: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994, 68:1660-1666.
36. Byrnes VA, Sardana W, Schleif WA, et al.: Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob Agents Chemother 1993, 37:1576-1579.
37. Saag MS, Emini EA, Laskin OL, et al.: A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N Engl J Med 1993, 329:1065-1072.
38. Demeter LM, Shafer RW, Para M, et al.: Delavirdine (DLV) susceptibility of HIV-1 isolates obtained from patients (PTS) receiving DLV monotherapy (AIDS Clinical Trials Group 260). 4th International Workshop on HIV Drug Resistance. Sardinia, July 1995 [abstract 23].
39. Larder BA: 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992, 36:2664-2669.
40. Balzarini J, Karlsson A, Perez-Perez MJ, Camarasa MJ, Tarpley WG, De Clercq E. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J Virol 1993, 67:5353-5359.
41. Demeter LM, Gerondelis P, Dexter A, et al.: Combination therapy with delavirdine (DLV) and DDI, but not zidovudlne, fails to prevent the emergence of Y181C in nucleoside experienced patients. 4th International Workshop on HIV Drug Resistance. Sardinia, July 1995 [abstract 31].
42. Kahn JO, Lagakos SW, Richman DD, et al.: A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992, 327:581-587.
43. Japour AJ, Welles S, D'Aquila RT, et al.: Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients following long-term zidovudine treatment. J Infect Dis 1995, 171:1172-1179.
44. D'Aquila RT, Johnson VA, Welles SL, et al.: Zidovudine resistance and human immunodeficiency virus type 1 disease progression during antiretroviral therapy. Ann Intern Med 1995, 122:40-408.
45. 1) in ZDV-pretreated HIV-posilive patients. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1995 [abstract 1169].
46. Schuurman R, Nijhuis M, van Leeuwen R, et al.: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995, 171:1411-1419.
47. 3. 2nd National Conference on Human Retroviruses. Washington, DC, January 1995 [abstract LB31].
48. Kuritzkes DR, Quinn JB, Benoit SL: Drug resistance and virologic response to NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996, 10:975-981.
49. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of zidovudine-3TC combination therapy. Science 1995, 269:696-699.
50. 3. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1996 [abstract 198].
51. Spence RA, Kati WM, Anderson KS, Johnson KA: Mechanism of inhibition of HIV-1 reverse transcriptase nonnucleoside inhibitors. Science 1995, 267:988-993.
52. Havlir D, Cheeseman SH, McLaughlin M, et al.: High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995, 171:537-545.